Top 5 Integrated Utility Stocks To Own For 2015

Top 5 Integrated Utility Stocks To Own For 2015: Seattle Genetics Inc.(SGEN)

Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc .; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.

Advisors' Opinion:

• [By Roberto Pedone]

  One biotechnology player that insiders are snapping up a huge amount of stock in here is Seattle Genetics (SGEN), which develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Insiders are buying this stock into huge strength, since shares are up sharply by 72% so far in 2013.

  Seattle Genetics has a market cap of $4.9 billion and an enterprise value of $4.5 billion. This stock trades at a premium valuation, with a price-to-sales of 19.09 and a price-to-book of 21.65. Its estimated growth rate for this! year is -37%, and for next year it's pegged at -6.3%. This is a cash-rich company, since the total cash position on its balance sheet is $373.85 million and its total debt is zero.

  A director just bought 1,005,901 shares, or about $43.44 million worth of stock, at $42.31 to $43.98 per share.

  From a technical perspective, SGEN is currently trending above its 200-day moving average and just below its 50-day moving average, which is neutral trendwise. This stock has been downtrending over the last few weeks, with shares dropping from its high of $45.37 to its intraday low of $39.85 a share. During that move, shares of SGEN have been consistently making lower highs and lower lows, which is bearish technical price action.

  If you're bullish on SGEN, then I would look for long-biased trades as long as this stock is trending above its 200-day of $38.40 or above more near-term support at $36.79 and then once it takes out its 50-day at $41.02 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 856,995 shares. If we get that move soon, then SGEN will set up to re-test or possibly take out its next major overhead resistance levels at $45.37 $46.48 a share. Any high-volume move above those levels will then give SGEN a chance to tag its 52-week high at $49.23 a share.

• [By Sean Williams]

  These might not be household names in the U.S., but they do brandish global licensing partnerships with companies that might be more familiar to you. Takeda, for example, has licensing agreements in place with Orexigen Therapeutics (NASDAQ: OREX  ) , which recently filed a New Drug Application for its chronic weight management (i.e., anti-obesity) pill, Contrave, in the U.S. Takeda owns the right to Contrave outside of North America. In addition, Takeda is a collaborative partner of antibody-drug conjugate developer Seattle Genetics (NASDAQ: SGEN  ) with regard to FDA-! approved ! Hodgkin lymphoma drug Adcetris.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-5-integrated-utility-stocks-to-own-for-2015.html